About Biologic Medicines

At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.

Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.

We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.

 

Summary


 
 
 
 
 
 

References
1.EMA. Biosimilars in the EU: Information guide for healthcare professionals. Available at: http://bit.ly/2qXnNpI. Accessed March 2018. 2.FDA. Vaccines, Blood & Biologics. Available at: http://bit.ly/2AYocKr. Accessed March 2018 3.Walsh, G. Nat Biotechnol 2014;32: 992–1000. 4.Morrow, T. Defining the difference: What Makes Biologics Unique. Biotechnology Healthcare. 2004;1(4):24-29. Available at: http://bit.ly/2D2hhAl. Accessed March 2018. 5.Medicines for Europe. Biosimilar Medicines Handbook. Available at: http://bit.ly/1QCnNMR. Accessed March 2018. 6.Apobiologix. Manufacturing. Available at: http://bit.ly/2ryyAUW . Accessed March 2018. 7.Schiestl M, et al. Nat Biotechnol 2011;29:310–2. 8.Weise M, et al. Blood 2012;120;5111–7. 9.EMA. Guideline on similar biological medicinal products. Available at: http://bit.ly/2ckWrzf.  Accessed March 2018. 10.TGA. Evaluation of Biosimilars. Available from: http://bit.ly/2Fi58wT. Accessed March 2018. 11.FDA. Biosimilar and Interchangeable Products. Available at: http://bit.ly/2G1oVhv. Accessed March 2018. 12.12. WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at: http://bit.ly/2oU099B. Accessed March 2018. 13.FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Available at: http://bit.ly/2qySWih. Accessed March 2018. 14.EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://bit.ly/1IiuZfS. Accessed March 2018. 15.Brinks V, et al. Pharm Res 2011;28:386–93. 16.Ventola CL. PT 2013;38:270–287. 17.Gudat U. Pharma Horizon 2016;1:35–38. 18.Schneider C. Ann Rheum Dis. 2013;72:315–8. 19.Kurki P, et al. BioDrugs 2017. 20.IGBA. Biosimilar medicines — a commitment to scientific excellence. Available at http://bit.ly/2oOanKu. Accessed March 2018. 21.Aus. Govt. Department of Health. Biosimilar medicines: the basics for health care professionals. Available at: http://bit.ly/2D3vdtK. Accessed March 2018. 22.Bui et al (2015). Key considerations in the preclinical development of biosimilars. Drug Discovery Today 20(SI):3–15. 23.Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. (2003). 24.Interchangeability of Biosimilars: A European Perspective. Available from: http://bit.ly/2FuiiGj. Accessed March 2018. 25.Ebbers HC, et al. Expert Opin Biol Ther. 2012;12(11):1473–85. 26.Glintborg B, et al. Ann Rheum Dis 2017; [Epub ahead of print]. 27.McCamish M, Woollett G. Clin Pharmacol Ther 2013;93:315–7. 28.Chirino AJ, Mire-Sluis A. Nature Biotechnol 2004;22:1383–91